Recent Developments in the Treatment of HER2-Positive Breast Cancer

Overview

This activity is designed to inform physicians about the recent developments, as well as anticipated advances, in the treatment of patients with HER2-positive breast cancer.

Instructions for Participation/How to Receive Credit:

You will need to login to participate in the activity.
Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
At the end of the activity, "educational content/video" will be available for your reference.
In order to receive a CME/CE certificate, participants must complete the activity.
Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This activity is directed toward medical oncologists, nurses, and nurse practitioners who manage and treat patients with HER2-positive breast cancer. Breast surgeons, surgical oncologists, radiation oncologists, pathologists, fellows, physician assistants, and other healthcare providers interested in the treatment of HER2-positive breast cancer are also invited to participate.

Learning Objectives

After participating in this CME/CE activity, learners should be better prepared to:

Describe the unmet needs in the treatment of patients with HER2-positive breast cancer
Review recent developments in the treatment of patients with HER2-positive breast cancer
Review current and emerging clinical trial information concerning the use of investigational therapeutic approaches to care for patients with HER2-positive breast cancer

The American Journal of Hematology/ Oncology^® Editorial Board

Debu Tripathy, MD
Professor and Chairman
Department of Breast Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosure: Grant/research support from Genentech/Roche, Pfizer, Puma Biotechnology Inc, and Novartis (clinical trial support contracted to the University of Southern California and MD Anderson Cancer Center); consultant for Eisai, OncoPlex Diagnostics, Merck, and Novartis.

Faculty

Mark D. Pegram, MD
Director, Breast Cancer Oncology Program
Stanford Women’s Cancer Center
Stanford, CA
Disclosure:Consultant: Genentech

Staff/Planner Disclosures and Conflict of Interest Resolution

The staff of Physicians’ Education Resource^®, LLC (PER^®), and the editorial staff of The American Journal of Hematology/Oncology^® have no relevant financial relationships with commercial interests to disclose.

It is the policy of PER^® to ensure fair balance, independence, objectivity, and scientific objectivity in all of our CME/CE activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.

Accreditation/Credit Designation

Physicians’ Education Resource^®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource^®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 1.0 Contact Hour.

Acknowledgment of Commercial Support

This activity is funded by Physicians' Education Resource^®, LLC.

Off-Label Disclosure and Disclaimer

This continuing medical and nursing education activity may or may not discuss investigational, unapproved or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, and management options for a specific patient's medical condition.

Disclaimer

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource^®, LLC.

Hardware And Software Requirements

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)